IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

Sohag University

Status

Unknown

Conditions

Systemic Lupus Erythematosus

Treatments

Diagnostic Test: Serum level of IL-17

Study type

Observational

Funder types

Other

Identifiers

NCT05045417

Soh-Med-21-09-22

Details and patient eligibility

About

Many laboratory markers can be measured for assessment of Lupus activity as aberrant manufacturing and imbalance of the cytokines of T-helper cell which already have been implicated within autoimmunity pathogenesis as IL-18 and IL-10 levels are usually elevated in lupus sufferers and correlated with SLEDAI score IL-17 has been linked to immune-mediated organ damage in several autoimmune diseases and recently it has been linked to pathogenesis of a murine model of lupus and human lupus Diverse cytokine abnormalities which common in lupus patients may skew T cells differentiation into IL-17-producing CD4+ and double negative T cells. This could promote the autoimmune process by activation of immune cells &stimulation of proliferation of B-cell and production of antibody

Enrollment

140 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

SLE will be diagnosed according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE
Age ≥ 18 years.
Patients who are able and willing to give written informed consent

Exclusion criteria

-Any other autoimmune disease rather than SLE. -

Systemic diseases
Malignancy
pregnancy

Trial design

140 participants in 2 patient groups

Cases with SLE

Description:

110 patients with SLE will be divided to : * 40 patients with lupus nephritis * 40 patients interstitial lung disease * 30 SLE patients without internal organ affection)

Treatment:

Diagnostic Test: Serum level of IL-17

control group

Description:

30 sex and age matched healthy individuals as a control group

Treatment:

Diagnostic Test: Serum level of IL-17